Connect with us

Cannabis

Why Pharma Is Taking Cannabis Seriously

Published

on

Curaleaf Reverse Split, SAM Keeps Losing

Avicanna is hosting its sixth annual Clinical Symposium in Toronto’s Mars Discovery District, and CEO Aras Azatyan joined the program to discuss the cannabis event and the broader moment in pharma. Azatyan noted in this episode of the Trade To Black Podcast that the US realignment has dramatically elevated the conversation with his pharmaceutical companies. institutional investors and pointed to the FDA’s recent breakthrough therapy designation for a THC-based drug candidate as a meaningful regulatory signal that cannabinoid-based medicine is being taken seriously at the highest levels.

Azatyan described the two-day symposium, which will take place on Thursday and Friday, as the leading academic and clinical forum in the field of cannabinoid research. Speakers include Dr. Hans Clarke, president of the Canadian Pain Society, neurologist Dr. Edmund Lewis, and a retired Canadian general, presenting sessions covering PTSD and veterans care, chronic pain, epilepsy, women’s health, and brain injury. Major industry players including Canopy, Curaleaf and Verdea are sponsoring the event.

When asked where the medical cannabis market is going, Azatyan outlined a three-level vision. A federally integrated medical marketplace modeled after Canada’s, including formularies, insurance coverage and compounding; and a pharmaceutical channel that pursues FDA-approved drug designations for specific clinical indications, with orphan disease exclusivity and co-development partnerships with existing pharmaceutical companies. He emphasized that Avicanna’s decade of Canadian clinical work, including nearly 15 government grants secured by principal investigators, allows the company to bring its MyMedi and Rolfito platforms, formulations and intellectual property across the border as US partnerships develop.

Azatyan closed by reflecting on what distinguishes Avicanna’s credibility in the clinical community. Unlike many Canadian licensed manufacturers that abandoned medical research when adult use opened up, Avicanna continued to fund and support physicians during that time, earning a level of trust that is now paying dividends as the realignment makes the medical opportunity a reality. He expressed hope that next year’s symposium could be hosted in a major US city, which shows how quickly he expects the landscape to change. Tune in for the full interview.

Cannabis

ALJ Hearing Day 2: What We Learned & What’s Next

Published

on

By

ALJ Hearing Day 2: What We Learned & What's Next

Shad Dales and Anthony Varrell returned on Tuesday Trade to blackDay two of ALJ hearings presented by Flowhub are underway in Arlington, Virginia. Eric Berlin of Denton, one of the nation’s most respected cannabis attorneys, shows us how the arguments are made in the hearing room. Michael Bronstein walks through the key moments of the first day, including admissions by a government witness about data gaps and how opponents tried to define those gaps.

Eric Berlin, a Dentons cannabis attorney with 33 years of legal experience and 18 years focused on cannabis reform, opened up by addressing the exclusion of proponents from hearings. According to DEA regulations, only parties adversely affected by the proposed rule are required to participate, and that proponents of the change, by definition, cannot be affected by it.

He described the DEA’s case as strong and backed by a scientific record supported by the HHS report, which spans 252 pages and cites thousands of supporting studies across two successive administrations. The conversation also revisited several arguments raised by opponents, including concerns that the FDA is relying on older data sets, questions about deviations from state-licensed programs, the variability of cannabis products complicating the single-scheduling decision and the lack of pregnancy-specific analysis in the government’s review.

For the second day in a row, Michael Bronstein, president of the American Hemp and Hemp Trade Association, joined in on highlights from the first day, including admissions by a government witness about data gaps and how opponents tried to present those gaps as grounds to discredit the HHS report in its entirety.

Bronstein noted that the opponents’ main strategy appeared to be to argue that newer data not included in the original report should invalidate its conclusions;

Listen to both interviews when you join.

Continue Reading

Cannabis

ALJ Hearing Week: What To Watch For

Published

on

By

ALJ Hearing Week: What To Watch For

Shad Dales and Anthony Varrell opened Monday Trade to blackPresented by Flowhub, our thoughts on Trulieve’s (NYSE: TRLV ) CEO Kim Rivers’ update on Friday confirmed that it has officially ended the automatic vesting plan it implemented back in March. The guys are also getting into a new bill from New Jersey that would allow liquor stores and some ABC-licensed bars to sell low-dose THC drinks, with up to 10 mg of THC per can. Then Michael Bronstein, president of the American Hemp and Hemp Trade Association, joins us for his Monday segment as we wrap up the ALJ’s first day.

Truelieve’s Kim Rivers says she has officially ended the automatic stock holding plan she introduced back in March. The plan was announced shortly after Trulieve began trading on the New York Stock Exchange. He posted late Friday that it was now over. The hosts broke down why the timing stood out and discussed how the layoff could signal Rivers’ confidence in the company’s trajectory.

Before bringing in their main guest, the hosts discussed a new bill out of New Jersey that would allow liquor stores and certain ABC-licensed bars to sell low-dose THC drinks with a limit of ten milligrams per can. The bill also extends the cannabis beverage regulations until November 13, 2026, and updates the display and serving size guidelines.

The keynote was presented by Michael Bronstein, president of the American Hemp and Hemp Trade Association, joining the first day of ALJ hearings in Arlington, Virginia. Bronstein laid out what the industry really needs to look out for when the proceedings begin; He emphasized the importance of DEA counsel making it clear that these hearings are specifically about rescheduling cannabis to Schedule III, not adult or recreational legalization, and noted the important nature of the United States government officially declaring that cannabis is safer than alcohol;

Be sure to hear our thoughts.



Continue Reading

Cannabis

Industry Sentiment vs Reality – Could The Hemp Ban Be Extended?

Published

on

By

Industry Sentiment vs Reality - Could The Hemp Ban Be Extended?

On Thursday Trade to blackpresented by Flowhub. Jim Higdon, co-founder of Cornbread Hemp, joins us to break down developments out of Washington. Reports have surfaced that the Trump administration has approached Congress about a proposed ban on cannabis. This immediately raises questions about whether the November 12 deadline could be pushed back, softened, or materially changed before their second guest segment. FundCanna CEO Adam Stettner also joins us from last week’s Chicago conference.

In the first segment, Adam Stetter, CEO of FundCanna, updated the IgniteIt conference in Chicago with a perspective that cut through the sheer festivity that many attendees brought home. While acknowledging that the optimism in the room was real and well-founded, Stettner said he pressed operators with a more difficult question. What does positive sentiment really mean for your business now? He found that most had difficulty answering specifically.

He described the gap not as a reason for pessimism, but as a call for discipline. long-term momentum is building, but near-term fundamentals have yet to change significantly, and operators who mistake optimism for improving business risk making ill-timed moves.

In part two, Jim Higdon, co-founder of Cornbread Hemp, broke down developments in Washington around hemp prohibition. He described the White House’s latest message to Congress as the fourth meaningful shot at a legislative fix this year, and noted that the coalition seeking a solution is growing and the administration is getting more specific, now openly calling for Andy Barr’s bill or an extension of the framework as part of an additional appropriations package.

Higdon emphasized that Cornbread Hemp is focused on maintaining two routes; supplement-style full-spectrum CBD products with one or about three milligrams of THC per serving, consistent with the CMS Medicare pilot program, and low-dose beverages dispensed through a three-tier alcohol system. He was careful to distinguish those products from smoking cannabis flower, which he said is the main source of friction between cannabis and the state-licensed cannabis industry.

This and more when you join.

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media